Figure 7.
ACF reduced CML development and decreased the number of long-term LSCs in vivo. CML mice were treated daily for 10 days with ACF or placebo and euthanized after 1 additional day. (A) Number of BM viable cells. (B) Relative number of GFP+ (leukemic) or GFP− (nonleukemic) cells in BM; data are expressed as fraction of the value obtained for placebo. (C) Apoptotic rate of GFP+ or GFP− BM cells. (D) Percentage (left) and relative number (right) of GFP+ or GFP−/LT-LSK cells in BM; data are expressed as fraction of the value obtained for placebo. (A-D) Values represent mean ± S.D. of data from 8 mice per experimental variant. ACF- vs PBS-treated mice: *P ≤ .05, **P ≤ .01, ***P ≤ .001; ACF-treated mice, GFP− vs GFP+ cells: §P ≤ .05, §§P ≤ .01.

ACF reduced CML development and decreased the number of long-term LSCs in vivo. CML mice were treated daily for 10 days with ACF or placebo and euthanized after 1 additional day. (A) Number of BM viable cells. (B) Relative number of GFP+ (leukemic) or GFP (nonleukemic) cells in BM; data are expressed as fraction of the value obtained for placebo. (C) Apoptotic rate of GFP+ or GFP BM cells. (D) Percentage (left) and relative number (right) of GFP+ or GFP/LT-LSK cells in BM; data are expressed as fraction of the value obtained for placebo. (A-D) Values represent mean ± S.D. of data from 8 mice per experimental variant. ACF- vs PBS-treated mice: *P ≤ .05, **P ≤ .01, ***P ≤ .001; ACF-treated mice, GFP vs GFP+ cells: §P ≤ .05, §§P ≤ .01.

Close Modal

or Create an Account

Close Modal
Close Modal